Agomab proposes Marino Garcia and Dr. Naimish Patel for board seats
Belgium-based Agomab Therapeutics plans to add the two as non-executive directors, pending a shareholder vote in September 2026.
SEC filing
Latest
2 stories
Monday, August 10
Tuesday, August 4
Dianthus reports Phase 3 CIDP interim data and gMG trial start, $1.2 billion cash
Dianthus disclosed a 75% response rate in an interim look at Part A of its Phase 3 CIDP trial and said its Phase 3 gMG trial began in June, alongside second-quarter results dated August 4, 2026.
SEC filing